Labiotech.eu

News and Trends 1 Dec 2022

FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field

The first fecal microbiota product, Rebyota, approved by the U.S. Food and Drug Administration (FDA) today has been hailed ‘fantastic news’ by those in the microbiome field. Ferring Pharmaceutical’s product is approved to stop Clostridiodes difficile infection (CDI) in people over 18 and to be given after they have completed an antibiotic treatment for the […]

December 1, 2022 - 6 minutesmins - By Liza Laws

News and Trends 1 Dec 2022

FDA clears SparingVision’s investigational new drug application to treat ocular diseases

SparingVision today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) for SPVN06. The genomic medicine company has had its developing vision-saving treatments for ocular diseases, lead gene independent therapy for the treatment of retinitis pigmentosa (RP), a form of rod-cone dystrophy (RCD) and the most prevalent […]

December 1, 2022 - 4 minutesmins - By Liza Laws

Best in Biotech 1 Dec 2022

Five apps powering the future of at-home HIV tests

The smartphone revolution is providing a promising tool to combat the human immunodeficiency virus (HIV) epidemic. We’ve listed five HIV test apps in development that could help people carry out at-home HIV tests and prevent the spread of the infection. The COVID-19 pandemic in the last two years has demonstrated how vital rapid diagnostic tests […]

December 1, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 1 Dec 2022

Trial for HPV16 positive oropharyngeal cancer completes enrolment for phase 2

Netherlands-based ISA Pharmaceuticals B.V., has announced that it has completed enrolment in its phase 2 clinical trial. Named OpcemISA. The trial aims to checkpoint inhibitor therapy in patients with metastatic/advanced 1st and 2nd line HPV16 positive oropharyngeal cancer (OPC). The clinical stage biotech company is developing immunotherapies to treat cancers and infectious diseases, and has […]

December 1, 2022 - 2 minutesmins - By Liza Laws

More News! 30 Nov 2022

FDA grants Sensorion Orphan Drug Designation for hearing loss drug

Sensorion a clinical-stage biotechnology company has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to OTOF-GT, its lead gene therapy program for hearing loss. The drug is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion is on track to file a clinical trial application (CTA) […]

November 30, 2022 - 3 minutesmins - By Liza Laws

Novella Thinking Outside the Field Plant Nutrients Without the Plant 002

More News! 30 Nov 2022

Nutri-tech startup, Novella, grows botanical ingredients without using the plants

Nutri-tech start-up Novella, Ltd. will start growing botanical ingredients while leaving the whole plant out of the equation through nutrient cultivation. This original platform in the plant world will help boost global accessibility to high-value nutraceuticals. Addressing the growing demand for botanical micronutrients, the new technology overcomes supply chain disruptions, circumvents climate change, and expands […]

November 30, 2022 - 4 minutesmins - By Liza Laws

News and Trends 30 Nov 2022

‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward

A huge step forward in dementia research has been hailed a truly historic moment by researchers working to find a cure for people with Alzheimer’s Disease. This is the first time a drug being trialed, lecanemab, has shown a reduction in the disease in the brain while slowing memory decline. Dr Susan Kohlhaas, director of […]

November 30, 2022 - 6 minutesmins - By Liza Laws

News and Trends 30 Nov 2022

TrialSpark acquires immunodermatology portfolio and creates Libertas Bio

TrialSpark has announced the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences. The Libertas Bio pipeline now includes global rights to gusacitinib, an oral phase 3-ready dual JAK/SYK inhibitor in development for chronic hand eczema (CHE), and ASN008, a phase 2-ready topical sodium […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 30 Nov 2022

SOTIO exercises option on ADC program

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB) for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies of solid tumor indications. In November 2021, SOTIO and LCB entered into a multi-target exclusive collaboration and license […]

November 30, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

AstraZeneca splashes out up to $320M on T-cell receptor therapy company

Neogene Therapeutics, Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), has entered into a definitive agreement to be acquired by Astrazeneca. AstraZeneca will acquire all outstanding equity of Neogene Therapeutics for a total consideration of up to $320 million, on a cash and debt free […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Nov 2022

Touchlight receives new grant to further develop doggybone DNA vaccine platform

UK-based biotechnology company, Touchlight, has received a new grant from the Bill & Melinda Gates Foundation. The company will use the money to further its pre-clinical development of its doggybone DNA vaccine platform. The program aims to build on evidence that Touchlight’s rapid enzymatic doggybone DNA vaccines can produce strong neutralizing antibodies and durable T […]

November 29, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field

FDA clears SparingVision’s investigational new drug application to treat ocular diseases

Five apps powering the future of at-home HIV tests

Trial for HPV16 positive oropharyngeal cancer completes enrolment for phase 2

FDA grants Sensorion Orphan Drug Designation for hearing loss drug

Nutri-tech startup, Novella, grows botanical ingredients without using the plants

‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward

TrialSpark acquires immunodermatology portfolio and creates Libertas Bio

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

SOTIO exercises option on ADC program

AstraZeneca splashes out up to $320M on T-cell receptor therapy company

Touchlight receives new grant to further develop doggybone DNA vaccine platform

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!